Effects of Teleintervention Maintenance Programs for Children (Age 6-12) and Adolescents (Age 13-18) With Overweight or Obesity-Promoting a Healthy Lifestyle: A Systematic Review.

Pediatr ObesSep 28, 2026
Clinical ResearchPediatricsPreventive Medicine / Public Health

Anna Wittmann, Pia Späth, Feline Zocher et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated teleintervention maintenance programs for children (ages 6-12) and adolescents (ages 13-18) with overweight or obesity. The review included 6 randomized controlled trials and 2 pre-post studies, revealing that these programs led to improvements in psychosocial outcomes and lifestyle modifications, with significant results such as BMI stabilization and reductions in body fat percentage.

Key findings

  • Teleintervention programs resulted in significant reductions in body fat percentage.
  • Improvements in psychosocial outcomes, including social well-being, were noted.
  • Participants showed lifestyle modifications, such as improved dietary patterns and reduced screen time.
  • Programs were associated with high feasibility and reduced healthcare visits and costs.

Why it matters

Understanding the effectiveness of teleintervention maintenance programs is essential for clinicians addressing pediatric obesity, as these programs can help sustain weight-related and behavioral improvements in young patients.

Source

PubMed · PMID 42802014

Published in Pediatr Obes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.